AzTrials
AzTrials

Sickle Cell DiseaseNCT03989986

iPeer2Peer Program for Youth With Sickle Cell Disease

A study testing iPeer2Peer Mentorship in people with Sickle Cell Disease, run by The Hospital for Sick Children at 4 sites in 2 countries.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially. Read more about this study

Who is it for?
Ages 12 to 18 years
Conditions the study is for
Sickle Cell Disease
What is being tested?
iPeer2Peer Mentorship
Could I receive a placebo?
No, everyone receives an active treatment
How many people
28 participants
Where
4 sitesin 2 countries
Study dates
1 Jan 2020to 31 Dec 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 12 to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Aged 12-18 years old
  • Diagnosed with SCD by a haematologist
  • Able to speak and read English
  • Access to Internet connection with computer capable of using free Skype software
  • Willing and able to complete online measures.

Who cannot join

  • Significant cognitive impairments
  • Major co-morbid illnesses (medical or psychiatric conditions) likely to influence HRQoL assessment
  • Currently participating in other peer support or self-management interventions.

Trial locations and contacts

4 sites in 2 countries.

4 sites in 2 countries

Canada3 sites
  • Children's Hospital of Eastern Ontario (CHEO)

    Ottawa, Ontario

  • Jim Pattison

    Saskatoon, Saskatchewan

  • The Hospital for Sick Children

    Toronto, Ontario

Other trials in Canada

United States1 site
  • Connecticut Children's Medical Center

    Hartford, Connecticut, 06106

Other trials in United States

About this study

Official title: Peer-to-Peer (iP2P) Mentoring Program for Youth With Sickle Cell Disease: A Pilot Feasibility Randomized Controlled Trial

The iPeer2Peer Sickle Cell Disease (SCD) study matches youth (12-18 years of age) with SCD to a mentor (trained young adult) who has learned to manage their SCD well, transitioned to adult care, and can support youth participants emotionally and socially. Participants will be randomly assigned one of two groups, either (1) The intervention group: Study group participants are matched with a mentor for 15 weeks, and are expected to have up to ten calls with one another; (2) The control group: This study group will be on a 15 week waitlist to receive a mentor. This study will first assess the feasibility of conducting this research with youth with SCD. Also, this study will assess the preliminary effectiveness of peer mentorship by comparing various health outcomes of the two study groups post-intervention.

Read the detailed description

Sickle Cell Disease (SCD) is a disease affecting red blood cells, where severe pain can develop due to blockage of red blood cells. This the most common genetic blood disease in North America, affecting mostly people of African descent. This type of pain can affect many aspects of one's life, and one's quality of life. Young people with SCD experience pain as they grow from childhood to adulthood, and experience daily chronic pain. There are many negative consequences of SCD, such as anxiety, depression, poor sleep, high stress, and limited social and physical activity. Peer support is a form of support that can provide someone with emotional, informational and social support. Peer support is a promising way of delivering emotional support, while helping someone learn how to cope and manage their disease. This is especially important for chronic diseases such as SCD, because young people will have to learn how to cope and manage their condition while growing up, and for the rest of their lives. A new way to provide face-to-face peer support is through the use of a virtual program using Skype via the Internet (to maintain face-to-face contact between mentors and mentees).

In this program, a young adult (a mentor) with a chronic disease is matched with a younger person living with the same disease (a mentee) online, through Skype. The mentors are nominated by their healthcare teams, and have successfully transitioned to adult care. They are trained to talk to young people about their disease and can give them some advice on how to manage, and grow up with the condition. This program has been tested with other groups with Juvenile Idiopathic Arthritis and Chronic Pain. A mentor and a mentee are matched for 15 weeks and are encouraged to have up to ten Skype calls together. The investigators do not know how well this program will work with young people with SCD. Therefore, the investigators would like to test out this program to see if it is feasible to conduct the iPeer2Peer SCD program in the future as a larger study with the SCD population.

Feasibility will be measured through the following: (1) recruitment and withdrawal rates; (2) rate of completion of weekly calls; (3) rate of completion of baseline measures; (4) estimates of intervention effects on health outcomes to inform the calculation of an appropriate sample size for the future definitive multi-centred randomized controlled trial (RCT) and (5) participants' perception regarding the acceptability of the SCD iP2P program and their level of engagement with the program (via a semi-structured interview). Descriptive statistics will be used to describe the sample characteristics at baseline. Rates of accrual, drop out, compliance, and missing data with 95% confidence intervals will be calculated.To inform sample size calculations and data analysis feasibility for a larger trial, data will be analyzed as in a larger study, and estimates of variance will be calculated. Secondary analysis will be conducted using an intent-to-treat approach. If assumptions for parametric statistics are met, linear regression models will be used to test intervention effects on pain impact, social support, self-efficacy, adherence and HRQL outcomes using an analysis of covariance approach with post-intervention measures compared between groups using baseline scores as covariates. The semi-structured individual (mentees) and focus group (mentors) interviews will determine (i) mentees' acceptability of and level of engagement in the iP2P program and (ii) mentors' likes and dislikes of program, improvement. This data, and subsequent analyses, will be used to refine the iP2P program prior to a full trial. A larger study will help to understand if peer support delivered by a mentor over Skype will help teenagers with SCD better manage their SCD, improve their health outcomes, and ultimately improve their quality of life living with SCD.

Being tested
iPeer2Peer Mentorship
Medical subject headings
Anemia, Sickle Cell

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • iPeer2Peer MentorshipBehavioural

    Mentors and participants can have up to ten Skype calls over the course of 15 weeks.

Study groups in NCT03989986
Study groupRoleWhat they receive
iPeer2Peer MentorshipExperimentalIn addition to standard care, participants in the experimental group will receive the iPeer2Peer program, a peer mentorship program that will provide modelling and reinforcement of self-management by pre-screened and trained peer mentors (young adults with SCD aged 19-25 who have learned to function successfully with their condition). Mentors will encourage participants to develop and engage in self-management skills and provide social support.
Receives: Behavioral: iPeer2Peer Mentorship
Waitlist Control GroupNo interventionThe control group participants will receive standard care and will be on a waitlist to receive the iPeer2Peer program until 15 weeks after completing their baseline questionnaires.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Recruitment Rate

    The number of participants recruited for the study during the recruitment study period.

    Measured: 2 years

  2. Rates of completion of mentor-mentee calls

    Compliance defined as 100% when a participant completes 10 calls within 15 weeks with their mentor

    Measured: 15 weeks

  3. Withdrawal Rate

    Number of participants that withdraw from the study over the study period

    Measured: 2 years

  4. Acceptability of iPeer2Peer SCD intervention

    Participants' perception regarding the acceptability of the SCD iP2P program and their level of engagement with the program (via a semi-structured interview).

    Measured: 15 weeks

Secondary outcomes (8)
  1. Sickle Cell Disease Pain Burden Interview- Youth

    7-item questionnaire, measuring pain burden

    Measured: Baseline and 15 weeks after baseline completion.

  2. Sickle Cell Disease Self-Efficacy Scale

    9-item questionnaire, measuring self-efficacy

    Measured: Baseline and 15 weeks

  3. PROMIS- Pediatric Peer Relationships 8a

    8-item questionnaire, measuring social support from peers

    Measured: Baseline and 15 weeks

  4. PROMIS depressive symptoms - 8a

    8-item questionnaire, measuring depression

    Measured: Baseline and 15 weeks

  5. PROMIS anxiety - 8a

    8-item questionnaire, measuring anxiety

    Measured: Baseline and 15 weeks

  6. PROMIS Pain Interference - 8a

    8-item questionnaire, measuring consequences of pain on relevant aspects of person's life.

    Measured: Baseline and 15 weeks

  7. PROMIS pain intensity - 1a

    1-item questionnaire, measuring intensity of pain over the past week

    Measured: Baseline and 15 weeks

  8. Transition-Q

    14-item questionnaire, measuring self-management

    Measured: Baseline and 15 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Jun 2019
  2. Study start1 Jan 2020
  3. Primary completion30 Jun 2022
  4. Study completion31 Dec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Investigator
Enrolment
28 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03989986
Sponsor's protocol ID
1727
Status last verified
Apr 2024
First submitted
17 Jun 2019
Last updated
17 Apr 2024
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Lalji R, Koh L, Francis A, Khalid R, Guha C, Johnson DW, Wong G. Patient navigator programmes for children and adolescents with chronic diseases. Cochrane Database Syst Rev. 2024 Oct 9;10(10):CD014688. doi: 10.1002/14651858.CD014688.pub2.

    PubMed 39382077

Questions about this trial

What is this clinical trial studying?

A study testing iPeer2Peer Mentorship in people with Sickle Cell Disease, run by The Hospital for Sick Children at 4 sites in 2 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 17 Apr 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Canada, United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Recruitment Rate (time frame: 2 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03989986, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Apr 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in